Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2015

01-02-2015 | PRECLINICAL STUDIES

In vitro evaluation of a tetrahydroisoquinoline derivative as a steroid sulfatase inhibitor and a selective estrogen receptor modulator

Authors: Charles Ouellet, Étienne Ouellet, Donald Poirier

Published in: Investigational New Drugs | Issue 1/2015

Login to get access

Summary

Selective estrogen receptor modulators (SERMs) are currently in use in the hormonal therapy of breast cancer. In that respect, a new hormone-related approach is the therapeutical inhibition of steroid sulfatase (STS), which converts inactive, sulfated steroids into active hormones. We investigated the potential of 6-EO-14, a non-steroidal STS inhibitor with SERM potential. The latter compound, which exhibits a sulfamate moiety, releases the phenol derivative 8-EO-14 after the irreversible inhibition of STS. STS was inhibited by 6-EO-14 (IC50 = 0.3 μM), but not 8-EO-14, in HEK-293 cells transfected with an STS expression vector. The SERM potential of 8-EO-14 was assessed in osteoblast-like Saos-2 cells by investigating its effect on cell proliferation and on the activity of alkaline phosphatase (ALP), a specific differentiation marker. Saos-2 cell proliferation was increased by 21 % following 8-EO-14 addition (1 μM), and 8-EO-14 induced ALP activity (31 % increase at 0.1 nM) via estrogen receptor alpha (ERα) similarly to the SERM raloxifene. As compared to estradiol (E2) (100 %), the relative binding affinity of 6-EO-14 and 8-EO-14) for ERα was found to be weak (0.09 and 0.01 %, respectively). When assessed in two estrogen-dependent human breast cancer cell lines (MCF-7 and T-47D), 8-EO-14 did not support MCF-7 cell proliferation, whereas both 8-EO-14 and 6-EO-14 exhibited estrogen-like growth stimulation in T-47D cells. These two compounds were also unable to block E2-induced cell proliferation, suggesting their lack of antiestrogenic activity. Despite the known potency of 6-EO-14 as an STS inhibitor, the observed trophic activity of this new scaffold towards ERα-positive cells needs to be carefully considered prior to its potential utilization as a therapeutic agent.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Jonat W, Pritchard KI, Sainsbury R, Klijn JG (2006) Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient. J Cancer Res Clin Oncol 132:275–286PubMedCrossRef
4.
Duggan C, Marriott K, Edwards R, Cuzick J (2003) Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 21:3588–3593PubMedCrossRef
5.
Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, Van Leeuwen FE (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive cancer Centres' ALERT group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356:881–887PubMedCrossRef
6.
Riggs BL, Khosla S, Melton LJ (2002) Third Sex steroids and the constructive and conservation of the adult skeleton. Endocr Rev 23:279–302PubMedCrossRef
7.
Obiorah I, Jordan VC (2011) Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturas 70:315–321
8.
Ghosh D (2007) Human sulfatases: a structural perspective to catalysis. Cell Mol Life Sci 64:2013–2022PubMedCrossRef
9.
Pasqualini JR, Gelly C, Nguyen BL, Vella C (1989) Importance of estrogen sulfates in breast cancer. J Steroid Biochem 34:155–163PubMedCrossRef
10.
Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72:23–27PubMedCrossRef
11.
Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M, Maloche C (1996) Concentration of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 81:1460–1464PubMed
12.
Santner SJ, Feil PD, Santen RJ (1984) In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 59:29–33PubMedCrossRef
13.
Ouellet E, Maltais R, Ouellet C, Poirier D (2013) Investigation of a tetrahydroisoquinoline scaffold as dual-action steroid sulfatase inhibitors generated by parallel solid-phase synthesis. Med Chem Commun 4:681–692CrossRef
14.
Ciobanu LC, Luu-The V, Martel C, Labrie F, Poirier D (2003) Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase. Cancer Res 63:6442–6446PubMed
15.
Wakeling AE, Bowler J (1988) Novel antioestrogens without partial agonist activity. J Steroid Biochem 31:645–653PubMedCrossRef
16.
Ciobanu LC, Luu-The V, Poirier D (2002) Nonsteroidal compounds designed to mimic potent steroid sulfatase inhibitors. J Steroid Biochem Mol Biol 80:339–353PubMedCrossRef
17.
Arcaro KF, Yi L, Seegal RF, Vakharia DD, Yang Y, Spink DC, Brosch K, Gierthy GF (1999) 2,2′,6,6′-Tetrachlorobiphenyl is estrogenic in vitro and in vivo. J Cell Biochem 72:94–102PubMedCrossRef
18.
Davis DD, Diaz-Cruz ES, Landini S, Kim YW, Brueggemeier RW (2008) Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells. J Steroid Biochem Mol Biol 108:23–31PubMedCentralPubMedCrossRef
19.
Qu Q, Perälä-Heape M, Kapanen A, Dahllund J, Salo J, Väänänen HK, Härkönen P (1998) Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 22:201–209PubMedCrossRef
20.
Qu Q, Härkönen PL, Väänänen HK (1999) Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem 73:500–507PubMedCrossRef
21.
Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA, Katzenellenbogen BS (2002) Antagonists selective for estrogen receptor alpha. Endocrinology 143:941–947PubMed
22.
Compton DR, Sheng S, Carlson KE, Rebacz NA, Lee IY, Katzenellenbogen BS, Katzenellenbogen JA (2004) Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor β antagonist activity. J Med Chem 47:5872–5893PubMedCrossRef
23.
Fujikawa H, Okura F, Kuwano Y, Sekizawa A, Chiba H, Shimodaira K, Saito H, Yanaihara T (1997) Steroid sulfatase activity in osteoblast cells. Biochem Biophys Res Commun 231:42–47PubMedCrossRef
24.
Nussbaumer P, Winiski AP, Billich A (2003) Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase. J Med Chem 46:5091–5094PubMedCrossRef
25.
Kumar R, Zakharov MN, Khan SH, Miki R, Jang H, Toraldo G, Singh R, Bhasin S, Jasuja R (2011) The dynamic structure of the estrogen receptor, J Amino Acids, Article ID 81254 0
26.
Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA (2006) International union of pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 58:773–781PubMedCrossRef
27.
Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Öhman L, Greene GL, Gustafsson JA, Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753–758PubMedCrossRef
Metadata
Title
In vitro evaluation of a tetrahydroisoquinoline derivative as a steroid sulfatase inhibitor and a selective estrogen receptor modulator
Authors
Charles Ouellet
Étienne Ouellet
Donald Poirier
Publication date
01-02-2015
Publisher
Springer US
Published in
Investigational New Drugs / Issue 1/2015
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-014-0187-1

Other articles of this Issue 1/2015

Investigational New Drugs 1/2015 Go to the issue

PRECLINICAL STUDIES

4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents

PHASE I STUDIES

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors

PHASE II STUDIES

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma

PRECLINICAL STUDIES

Novel benzoxazines as inhibitors of angiogenesis

PRECLINICAL STUDIES

Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer

PHASE I STUDIES

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits